Furthermore, BPR1K871 was identified as a multi-kinase inhibitor with a broad inhibition potential against several cancer-associated kinases such as ABL1, AXL, BRAF, CHEK2, CSF1R, DDR, FLT1, KIT, PDGFR, PLK4, RET, TRKA, VEGFR2 besides AURK and FLT3. This evidence concerns the gene BRAF and cancer.